Highlights：

1. Cover the most mutant types of drug resistant tuberculosis;

2. Over 90% mutation coverage rate on 6 major anti-TB first line drugs;

3. Only 2.5 h is required for the overall process;

4. NMPA approval and CE marked for IVD use.